3 news items
Gossamer Bio Secures $160M Partnership with Chiesi Group to Accelerate Development of Pulmonary Hypertension Treatment, $486M Potential for Seralutinib Collaboration
GOSS
6 May 24
), enabling the expansion of the seralutinib franchise to reach more patients with pulmonary hypertension world-wide. Patients will benefit from both
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
GOSS
6 May 24
. Patients will benefit from both Chiesi's expertise in global respiratory, rare disease, and inhaled drug development and commercialization and Gossamer's
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
GOSS
3 May 24
on the Company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: the potential benefits
- Prev
- 1
- Next